Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda
A Umubyeyi1, L Rigouts, I C Shamputa
1Department of Microbiology, CHU St Pierre, Brussels, Belgium. alainenyaruhirira@hotmail.com
Background:
Multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic problem in many parts of the world, necessitating the inclusion of second-line anti-tuberculosis drugs in specific treatment regimens.
Methods:
We studied the susceptibility of 69 MDR Mycobacterium tuberculosis isolates from Rwanda to second-line drugs by the BACTEC 460 method.
Results:
The results showed that 62 (89.9%) were resistant to rifabutin while a low rate (4.3%) of resistance was registered for ofloxacin; there was one case (1.4%) of resistance each for para-aminosalicylic acid, kanamycin, ethionamide, and clarithromycin.
Conclusions:
This information is important for devising an appropriate treatment regimen for MDR-TB patients in order to stop the spread of MDR strains and contain the acquisition of additional drug resistance in Rwanda.
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Mechanism of Antibiotic Resistance in MRSA
Clinical Significance of Antibiotic Resistance
Treatment Resistant Cancers

